CN112587512A - ASBDV pharmaceutical composition for treating cerebral apoplexy and preparation and application thereof - Google Patents
ASBDV pharmaceutical composition for treating cerebral apoplexy and preparation and application thereof Download PDFInfo
- Publication number
- CN112587512A CN112587512A CN202110162171.4A CN202110162171A CN112587512A CN 112587512 A CN112587512 A CN 112587512A CN 202110162171 A CN202110162171 A CN 202110162171A CN 112587512 A CN112587512 A CN 112587512A
- Authority
- CN
- China
- Prior art keywords
- asbdv
- pharmaceutical composition
- cerebral apoplexy
- treating cerebral
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000006011 Stroke Diseases 0.000 title claims abstract description 90
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 65
- 206010008190 Cerebrovascular accident Diseases 0.000 title claims abstract description 60
- 230000002490 cerebral effect Effects 0.000 title claims abstract description 60
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims abstract description 35
- 235000013793 astaxanthin Nutrition 0.000 claims abstract description 35
- 229940022405 astaxanthin Drugs 0.000 claims abstract description 35
- 239000001168 astaxanthin Substances 0.000 claims abstract description 35
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims abstract description 35
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims abstract description 26
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims abstract description 25
- 229950011318 cannabidiol Drugs 0.000 claims abstract description 25
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims abstract description 25
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims abstract description 25
- 239000000463 material Substances 0.000 claims abstract description 13
- 239000000203 mixture Substances 0.000 claims abstract description 9
- 239000007924 injection Substances 0.000 claims abstract description 8
- 238000002347 injection Methods 0.000 claims abstract description 8
- 239000002775 capsule Substances 0.000 claims abstract description 6
- 239000006187 pill Substances 0.000 claims abstract description 6
- 239000008187 granular material Substances 0.000 claims abstract description 5
- 239000007788 liquid Substances 0.000 claims abstract description 5
- 239000000843 powder Substances 0.000 claims abstract description 5
- REOZWEGFPHTFEI-JKSUJKDBSA-N Cannabidivarin Chemical compound OC1=CC(CCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-JKSUJKDBSA-N 0.000 claims description 20
- REOZWEGFPHTFEI-UHFFFAOYSA-N cannabidivarine Natural products OC1=CC(CCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-UHFFFAOYSA-N 0.000 claims description 13
- 235000013305 food Nutrition 0.000 claims description 3
- 239000002417 nutraceutical Substances 0.000 claims 1
- 235000021436 nutraceutical agent Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 18
- 239000003814 drug Substances 0.000 abstract description 14
- 241000699670 Mus sp. Species 0.000 description 28
- 125000003999 astaxanthin group Chemical group 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 8
- 206010008118 cerebral infarction Diseases 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 230000008499 blood brain barrier function Effects 0.000 description 7
- 210000001218 blood-brain barrier Anatomy 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 208000029028 brain injury Diseases 0.000 description 6
- 230000010410 reperfusion Effects 0.000 description 6
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 5
- 239000010931 gold Substances 0.000 description 5
- 229910052737 gold Inorganic materials 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 208000026106 cerebrovascular disease Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000005021 gait Effects 0.000 description 4
- 208000028867 ischemia Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 201000006474 Brain Ischemia Diseases 0.000 description 3
- 206010008120 Cerebral ischaemia Diseases 0.000 description 3
- 206010063837 Reperfusion injury Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000003727 cerebral blood flow Effects 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 3
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 235000021466 carotenoid Nutrition 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000010212 ginaton Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000003447 ipsilateral effect Effects 0.000 description 2
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 229960005375 lutein Drugs 0.000 description 2
- 230000007971 neurological deficit Effects 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 2
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 208000024806 Brain atrophy Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
- 206010008092 Cerebral artery thrombosis Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 102000017055 Lipoprotein Lipase Human genes 0.000 description 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 150000001200 N-acyl ethanolamides Chemical class 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 241000694540 Pluvialis Species 0.000 description 1
- 241000316848 Rhodococcus <scale insect> Species 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 1
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000006909 anti-apoptosis Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000002621 endocannabinoid Substances 0.000 description 1
- 229960003699 evans blue Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 208000037907 haemorrhagic injury Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- NTHXOOBQLCIOLC-UHFFFAOYSA-N iohexol Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NTHXOOBQLCIOLC-UHFFFAOYSA-N 0.000 description 1
- 229960001025 iohexol Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000003137 locomotive effect Effects 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 238000013227 male C57BL/6J mice Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000010603 microCT Methods 0.000 description 1
- 210000003657 middle cerebral artery Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 230000003188 neurobehavioral effect Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 238000012346 open field test Methods 0.000 description 1
- 238000012634 optical imaging Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- -1 xanthophyll carotenoid Chemical class 0.000 description 1
- 235000008210 xanthophylls Nutrition 0.000 description 1
- 235000010930 zeaxanthin Nutrition 0.000 description 1
- 229940043269 zeaxanthin Drugs 0.000 description 1
- 239000001775 zeaxanthin Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Urology & Nephrology (AREA)
- Botany (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses an ASBDV pharmaceutical composition for treating cerebral apoplexy, and a preparation and application thereof. The ASBDV medicine composition for treating cerebral apoplexy consists of astaxanthin and cannabidiol. The preparation is the ASBDV pharmaceutical composition for treating cerebral apoplexy, and auxiliary materials are added into the ASBDV pharmaceutical composition to prepare tablets, oral liquid, capsules, granules, powder, pills or injections. The application is the application of the ASBDV pharmaceutical composition for treating cerebral apoplexy in preparing products for preventing/treating cerebral apoplexy. The astaxanthin and cannabidiol composition (ASBDV) has a remarkable effect of treating cerebral apoplexy.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to an ASBDV pharmaceutical composition for treating cerebral apoplexy, and a preparation and application thereof.
Background
Cerebral apoplexy is a group of diseases which take cerebral ischemia and hemorrhagic injury symptoms as main clinical manifestations, is also called cerebral apoplexy or cerebrovascular accident, has extremely high fatality rate and disability rate, and is mainly divided into hemorrhagic cerebral apoplexy (cerebral hemorrhage or subarachnoid hemorrhage) and ischemic cerebral apoplexy (cerebral infarction and cerebral thrombosis). The cerebral apoplexy is acute and the fatality rate is high, which is one of the most important lethal diseases in the world. High mortality rate and gradually increased prevention and treatment cost become one of the most serious diseases harming the health of people, cause huge economic burden and mental stress to the society and families, and become an important public health problem seriously affecting the national civilization[1-2]Therefore, the research on effective therapeutic drugs is of great social significance.
Disclosure of Invention
The first purpose of the invention is to provide an ASBDV pharmaceutical composition for treating cerebral apoplexy; the second aim is to provide the preparation of the ASBDV pharmaceutical composition for treating cerebral apoplexy; the third purpose is to provide the application of the ASBDV pharmaceutical composition for treating cerebral apoplexy.
The first purpose of the invention is realized by that the ASBDV medicine composition for treating cerebral apoplexy consists of astaxanthin and cannabidiol.
The second purpose of the invention is realized by adding auxiliary materials into the ASBDV pharmaceutical composition to prepare tablets, oral liquid, capsules, granules, powder, pills or injections.
The third purpose of the invention is realized by the application of the ASBDV pharmaceutical composition for treating cerebral apoplexy in the preparation of products for preventing/treating cerebral apoplexy.
The present study shows that high intake of the six major carotenoids (i.e. lycopene, carotene, lutein, zeaxanthin and astaxanthin) is associated with a reduced risk of stroke and other cardiovascular events.
Astaxanthin (astaxanthin) is a xanthophyll carotenoid widely found in rhodococcus pluvialis, seafood, quail and some complex plants. It has antioxidant, antiinflammatory, anti-apoptosis, and neuroprotective effects. Some recent studies have shown that astaxanthin can prevent ischemia-reperfusion injury in mice by activating the mTOR pathway, exhibiting therapeutic effects on cerebral stroke.
Cannabidivarin (CBDV), the first isolated in 1969, has so far been poorly known for its pharmacological activity, CBDV has been shown to inhibit the major synthase of endocannabinoids, 2-arachidon, diacylglycerol lipase a, etc., whereas a study in 2018 has shown that chronic use of CBDV can restore behavioral patterns and brain atrophy symptoms in rats with rist syndrome (an autism), although these pharmacological traits have not been clinically proven, they illustrate the diversity of CBDV pharmacology. The invention proves the curative effect of the astaxanthin and cannabidiol combined drug (ASBDV) on cerebral arterial thrombosis for the first time.
Drawings
FIG. 1 is a graph showing the effect of the ASBDV pharmaceutical composition of the present invention on the survival rate of mice after stroke;
FIG. 2 is a graph showing the effect of the ASBDV pharmaceutical composition of the present invention on the body weight of mice after stroke;
FIG. 3 is a graph showing the effect of the ASBDV pharmaceutical composition of the present invention on mNSS of post-stroke mice;
fig. 4 is a schematic diagram showing the comparative effect of the ASBDV pharmaceutical composition of the present invention on the 5 th day movement distance of the post-stroke mouse in the field test;
FIG. 5 is a graph showing the comparative effect of the ASBDV pharmaceutical composition of the present invention on the mean velocity at day 5 of the post-stroke mouse field test;
fig. 6 is a schematic diagram showing the comparative effect of the ASBDV pharmaceutical composition of the present invention on the limb support distance at day 7 of the post-stroke mouse open field test;
fig. 7 is a graph showing the maximum contact area versus effect of the ASBDV pharmaceutical composition of the present invention on abnormal improvement in post-stroke mice;
fig. 8 is a graph showing the effect of the ASBDV pharmaceutical composition of the present invention on improving abnormal hind limb paw prints in post-stroke mice;
fig. 9 is a schematic diagram showing the effect of the ASBDV pharmaceutical composition of the present invention on brain injury in mice after stroke.
Detailed Description
The present invention is further illustrated by the following examples and the accompanying drawings, but the present invention is not limited thereto in any way, and any modifications or alterations based on the teaching of the present invention are within the scope of the present invention.
The ASBDV medicine composition for treating cerebral apoplexy consists of astaxanthin and cannabidiol.
The mass ratio of the astaxanthin to the cannabidiol is 1: (2-5).
The mass ratio of the astaxanthin to the cannabidiol is 1: 3.
The preparation of the ASBDV pharmaceutical composition for treating cerebral apoplexy is prepared by adding auxiliary materials into the ASBDV pharmaceutical composition to prepare tablets, oral liquid, capsules, granules, powder, pills or injections.
The application of the ASBDV pharmaceutical composition for treating cerebral apoplexy disclosed by the invention is the application of the ASBDV pharmaceutical composition for treating cerebral apoplexy in preparing a product for preventing/treating cerebral apoplexy.
The product is food, medicine or health food.
The invention is further illustrated by the following specific examples:
example 1
Weighing astaxanthin and water-soluble cannabidiol according to the mass ratio of 1:2, and then uniformly mixing to obtain the target ASBDV pharmaceutical composition for treating cerebral apoplexy.
Example 2
Weighing astaxanthin and water-soluble cannabidiol according to the mass ratio of 1:3, and then uniformly mixing to obtain the target ASBDV pharmaceutical composition for treating cerebral apoplexy.
Example 3
Weighing astaxanthin and water-soluble cannabidiol according to the mass ratio of 1: 4, and then uniformly mixing to obtain the target ASBDV pharmaceutical composition for treating cerebral apoplexy.
Example 4
Weighing astaxanthin and water-soluble cannabidiol according to the mass ratio of 1: 5, and then uniformly mixing to obtain the target ASBDV pharmaceutical composition for treating cerebral apoplexy.
Example 5
The ASBDV pharmaceutical composition for treating cerebral apoplexy prepared in the embodiment 2 is added with pharmaceutically acceptable auxiliary materials to prepare tablets.
Example 6
The ASBDV pharmaceutical composition for treating cerebral apoplexy prepared in the embodiment 1 is added with pharmaceutically acceptable auxiliary materials to prepare oral liquid.
Example 7
The ASBDV pharmaceutical composition for treating stroke prepared in example 4 is added with pharmaceutically acceptable excipients to prepare a capsule.
Example 8
The ASBDV pharmaceutical composition for treating cerebral apoplexy prepared in the embodiment 2 is added with pharmaceutically acceptable auxiliary materials to prepare granules.
Example 9
The ASBDV pharmaceutical composition for treating cerebral apoplexy prepared in the embodiment 3 is added with pharmaceutically acceptable auxiliary materials to prepare powder.
Example 10
The ASBDV medicine composition for treating cerebral apoplexy prepared in the embodiment 2 is added with pharmaceutically acceptable auxiliary materials to prepare pills.
Example 11
The ASBDV pharmaceutical composition for treating cerebral apoplexy prepared in the embodiment 3 is added with pharmaceutically acceptable auxiliary materials to prepare an injection.
Example 12
The ASBDV medicine composition for treating cerebral apoplexy prepared in the embodiment 4 is added with pharmaceutically acceptable auxiliary materials to prepare pills.
Example 13
A capsule is prepared by adding pharmaceutically acceptable auxiliary materials into the ASBDV pharmaceutical composition for treating cerebral apoplexy, which is prepared in the embodiment 1.
Example 14
The ASBDV pharmaceutical composition for treating stroke prepared in example 3 was tested as follows:
1. materials and methods
1.1 animals
Male C57BL/6J mice, 8 weeks old, purchased from the department of laboratory animals, university of Kunming medical, were 22.5-25 g in weight, kept in a room of fixed humidity (40% + -5%), temperature (22 deg.C + -2 deg.C) and natural light, and had free access to water and food. The animal study protocol was approved by the university of Kunming medical laboratory animal ethics Committee.
1.2 establishment of cerebral ischemia-reperfusion injury model and group administration
Mice were anesthetized with a small animal anesthesia machine filled with 2% isoflurane, the skin of the mouse head was cut open, and the basal cerebral blood flow was monitored with a laser doppler flow meter (Moor Instruments, uk). The left common carotid, external carotid, internal carotid and pterygopalatine arteries of the mice were isolated, the distal external carotid was ligated with medical sutures, the proximal cut was made and a MCAO plug was inserted to block blood flow in the middle cerebral artery. And after 30 min, the plug is drawn out to realize reperfusion, and the mice which detect the cerebral blood flow until the cerebral blood flow is recovered to about 80 percent of the basic value are considered to realize the purpose of ischemia reperfusion, so that the modeling is successful. Finally, the skin was sutured with 4-0 sutures. The sham group (sham) was identical to the model rats except that no wire plugs were inserted. 140 mice were used for this study, 20 of which were discarded without effecting reperfusion of blood flow, and 120 were equally divided for the official experiment in 6 groups as follows: sham group (sham), model group (model), 3 mL. kg-1Gold multiple control drug group (ginaton), 3 mL. kg-1 ASBDV pharmaceutical composition group (ASBDV) for treating cerebral apoplexy, prepared in example 3, 3 mL kg-1 Astaxanthin group (AST) and 3 mL kg-1 time cannabidiol group (CBDV). For 4 administration groups, immediately after moldingThe corresponding drug was injected into the tail vein 1 time, and thereafter, the tail vein was administered 1 time in the morning and evening each day until day 7, and the Sham (Sham) and Model (Model) groups were administered with an equal amount of physiological saline.
Neurological deficit scores mice were scored for neurological deficit on days 1, 4, and 7 following cerebral ischemia-reperfusion according to a modified neurological severity score sheet (mNSS) including 4 items of tail overhang, walking, balance beam test, and reactive deficit. The score ranges from 0 to 14 and is positively correlated with the severity of ischemia reperfusion injury.
Open field experiments on day 5 after ischemia reperfusion, mice were placed in a 40 cm x 40 cm open field with a high speed camera suspended above. To eliminate the odor effect, the open field bottom was wiped with 75% alcohol before testing each animal. The recording time was set to 30 min and the total distance and average speed were recorded using ANY ANY-maze behavior tracking software (Stoelting, USA).
Automatic gait analysis mice were trained on the Catwalk system (Noldus, the netherlands) race for 2 days prior to ischemia reperfusion to become familiar with the race track, and on day 7 after ischemia reperfusion, mice were subjected to automatic quantitative gait recordings by the Catwalk system and analyzed for support distance, maximum contact area, total area of paw prints, stride length, and swing speed using Catwalk XT Version 9.1 software.
Measurement of cerebral infarction volume mice were euthanized and the brains were removed and cut into 5 coronal sections 2 mm thick in a brain mold and stained with TTC for 15 min in a 37 ℃ incubator. The areas of the contralateral hemisphere (Ci), ipsilateral hemisphere (Ii) and ipsilateral non-ischemic region (Ni) were determined using Image J software (NIH) and infarct volume (%) was calculated using the following equation:
blood Brain Barrier (BBB) leakage evaluation after stroke on the 6 th day according to 300mL kg-1 tail vein injection of 0.6% Evans blue solution, after 24 h taking the brain and cut into 5 2 mm thick coronary slices, using IVIS LuminaK Series III small animal in vivo optical imaging system (according to the following fluorescence imaging parameters uptake total luminous efficiency), exposure time automatic, excitation light 700 nm, emission light 790 nm.
Analysis of cerebral edema after inhalation of anesthetized mice with 2% isoflurane, 15 mL kg-1Tail vein injection of contrast agent iohexol injection. The brain was then scanned using the Quantum FX small animal in vivo three-dimensional tomography system (Micro-CT, PerkinElmer, usa) at the following parameters: the voltage is 90 kV, the current is 180 muA, the visual field is 2 cm, and the scanning time is 4.5 min.
2. Results
2.1 Effect of each administration group on survival, body weight and mNSS in post-stroke mice
As can be seen from FIG. 1, the mortality rate was higher (P < 0.001) in the Model group mice (Model) than in the Sham group (Sham). The ASBDV pharmaceutical composition for treating stroke (ASBDV) (P < 0.001) prepared in example 3 improved survival rate to more than 50% and the hypocannabidiol (CBDV) and Astaxanthin (AST) groups were slightly less effective (P < 0.05), compared to the Model group (Model), and the survival rate was improved after treatment with ASBDV, Astaxanthin (AST) and hypocannabidiol (CBDV) prepared in example 3. As can be seen from fig. 2, the body weight of the model group was significantly reduced, and compared to the model group, the ASBDV pharmaceutical composition for treating stroke prepared in example 3 exhibited significant efficacy (P < 0.05 or P < 0.01) from day 4, and Cannabidiol (CBDV) and Astaxanthin (AST) were effective (P < 0.01) from day 5, and on the mNSS scale (fig. 3), the model group mice exhibited severe impaired neurobehavioral (P < 0.001), and on day 4 after surgery, the ASBDV pharmaceutical composition for treating stroke (asv) (P < 0.001) and Cannabidiol (CBDV) (P < 0.05) prepared in example 3 significantly improved neurological abnormalities, and this beneficial effect was sustained until day 7 (P < 0.001 or P < 0.01). The ASBDV pharmaceutical composition (ASBDV) for treating cerebral apoplexy prepared in the example 3 and the gold poly (Ginaton) as a positive drug have no obvious difference on the 3 indexes.
2.2 Effect of each administration group on post-stroke mouse locomotor function
Open field experiments (fig. 4 and 5) on day 5 after stroke show that the moving distance and the average speed of the model group mice are obviously reduced within 30 min (P< 0.01). However, the ASBDV pharmaceutical composition for treating cerebral Apoplexy (ASBDV) prepared in example 3 was compared with the control drug group (Ginanton) (P)<0.001), Astaxanthin (AST) group and cannabidiol sub (CBDV) group (B: (B)P Less than 0.05) the moving distance and the average speed of the mouse are obviously improved. Gait analysis of mice on day 7 showed that the ASBDV pharmaceutical composition (ASBDV), Astaxanthin (AST) and Cannabidiol (CBDV) groups for treating stroke prepared in example 3 could significantly improve the base of support (BOS) (P) caused by stroke<0.001, fig. 6), and in addition, the ASBDV pharmaceutical composition for treating cerebral Apoplexy (ASBDV) prepared in example 3 can improve the maximum contact area of abnormality (P < 0.05) and Total area of paw prints of hind limbs: (P Less than 0.01), the effect is obviously better than that of Astaxanthin (AST) group and Cannabidiol (CBDV) group (BP< 0.05, FIGS. 7, 8). In the above kinematic evaluation indexes, the ASBDV pharmaceutical composition for treating cerebral Apoplexy (ASBDV) prepared in example 3 is equivalent to the gold pleiotropium positive drug.
2.3 Effect of Each administration group on post-stroke brain injury in mice
Mice were evaluated for brain injury severity by TTC staining and detection of BBB leakage. The model group mice had significantly increased cerebral infarct volume (A, B of fig. 9) and BBB leakage (C, D of fig. 9) compared to Sham (Sham) ((ii) in contrast to Sham)P< 0.001). Example 3 the resulting pharmaceutical composition of ASBDV for stroke treatment (ASBDV) can reverse this brain injury: (P< 0.001 andP< 0.01). While the Cannabidiol (CBDV) and Astaxanthin (AST) groups also reduced the volume of cerebral infarction, the ASBDV pharmaceutical composition for treating cerebral Apoplexy (ASBDV), Cannabidiol (CBDV) and Astaxanthin (AST) groups prepared in example 3 all had a vague effect in terms of BBB leakage, showing a beneficial effect. In addition, the preparation of example 3 for the treatment of strokeASBDV pharmaceutical composition (ASBDV) and gold were much the same in reversing cerebral infarct volume and BBB leakage.
3. Conclusion
The ASBDV pharmaceutical composition (ASBDV) for treating stroke prepared in example 3 has a significant effect on post-stroke cerebellar injury, and the ASBDV pharmaceutical composition (ASBDV) (P < 0.001) for treating stroke prepared in example 3 can increase the survival rate to more than 50% and show a significant effect on the fourth day (fig. 1, 2 and 3).
ASBDV pharmaceutical composition for treating cerebral Apoplexy (ASBDV) prepared in example 3 in improving motor function<0.001), Astaxanthin (AST) group and cannabidiol sub (CBDV) group (B: (B)P < 0.05) the moving distance and average speed of the mice were significantly increased (fig. 4, 5).
Gait analysis of mice shows that the ASBDV pharmaceutical composition (ASBDV), the Astaxanthin (AST) group and the Cannabidiol (CBDV) group for treating stroke prepared in example 3 can significantly improve the base of support (BOS) (P) caused by stroke<0.001, 6), and in addition, the ASBDV pharmaceutical composition group for treating cerebral Apoplexy (ASBDV) prepared in example 3 can improve the abnormal maximum contact area ((ASBDV)P< 0.05) and Total area of paw prints of hind limbs: (PLess than 0.01), the effect is obviously better than that of Astaxanthin (AST) group and Cannabidiol (CBDV) group (BP< 0.05, FIGS. 7, 8). In the above kinematic evaluation indexes, the ASBDV pharmaceutical composition for treating cerebral Apoplexy (ASBDV) prepared in example 3 is equivalent to the gold pleiotropium positive drug.
The severity of brain injury to mice is evaluated by TTC staining and BBB leakage detection, and the results show that the ASBDV pharmaceutical composition (ASBDV), Cannabidiol (CBDV) and Astaxanthin (AST) groups for treating cerebral apoplexy prepared in example 3 all have obvious efficacy, and the ASBDV pharmaceutical composition (ASBDV) for treating cerebral apoplexy prepared in example 3 has more obvious effect, can obviously reverse the brain injury, and is superior to the Cannabidiol (CBDV) and Astaxanthin (AST) groups in results (figure 9).
Example 15
The results of experiments carried out by the ASBDV pharmaceutical compositions for treating cerebral apoplexy prepared in example 1, example 2 and example 4 are the same as example 14, and all the results show that the ASBDV pharmaceutical compositions for treating cerebral apoplexy have significant efficacy in treating cerebral apoplexy.
Claims (6)
1. The ASBDV pharmaceutical composition for treating cerebral apoplexy is characterized by consisting of astaxanthin and cannabidiol.
2. The ASBDV pharmaceutical composition for treating cerebral apoplexy according to claim 1, wherein the weight ratio of astaxanthin and cannabidivarin is 1: (2-5).
3. The ASBDV pharmaceutical composition for treating cerebral apoplexy according to claim 1, wherein the weight ratio of the astaxanthin to the cannabidiol is 1: 3.
4. The preparation of the ASBDV pharmaceutical composition for treating the cerebral apoplexy as claimed in any one of claims 1 to 3, wherein the preparation of the ASBDV pharmaceutical composition for treating the cerebral apoplexy is prepared by adding auxiliary materials into the ASBDV pharmaceutical composition to prepare tablets, oral liquid, capsules, granules, powder, pills or injections.
5. The application of the ASBDV composition for treating cerebral apoplexy of any claim 1 to 3, which is characterized in that the ASBDV composition for treating cerebral apoplexy is applied to the preparation of products for preventing/treating cerebral apoplexy.
6. The use of ASBDV composition for the treatment of stroke as claimed in claim 5 wherein the product is a food, pharmaceutical or nutraceutical product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110162171.4A CN112587512A (en) | 2021-02-05 | 2021-02-05 | ASBDV pharmaceutical composition for treating cerebral apoplexy and preparation and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110162171.4A CN112587512A (en) | 2021-02-05 | 2021-02-05 | ASBDV pharmaceutical composition for treating cerebral apoplexy and preparation and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112587512A true CN112587512A (en) | 2021-04-02 |
Family
ID=75207797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110162171.4A Pending CN112587512A (en) | 2021-02-05 | 2021-02-05 | ASBDV pharmaceutical composition for treating cerebral apoplexy and preparation and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112587512A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101361726A (en) * | 2008-09-05 | 2009-02-11 | 南通大学 | Use of astaxanthin in preparing medicine capable of preventing and treating cerebral apoplexy |
| CN101489548A (en) * | 2006-06-08 | 2009-07-22 | 纽若科伊公司 | Use of cannabinoid receptor agonists as hypothermia inducing drugs for the treatment of ischemia |
| US20140228438A1 (en) * | 2011-07-01 | 2014-08-14 | Gw Pharmaceuticals Limited | Cannabinoids for use in the treatment of neurodegenerative diseases or disorders |
-
2021
- 2021-02-05 CN CN202110162171.4A patent/CN112587512A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101489548A (en) * | 2006-06-08 | 2009-07-22 | 纽若科伊公司 | Use of cannabinoid receptor agonists as hypothermia inducing drugs for the treatment of ischemia |
| CN101361726A (en) * | 2008-09-05 | 2009-02-11 | 南通大学 | Use of astaxanthin in preparing medicine capable of preventing and treating cerebral apoplexy |
| US20140228438A1 (en) * | 2011-07-01 | 2014-08-14 | Gw Pharmaceuticals Limited | Cannabinoids for use in the treatment of neurodegenerative diseases or disorders |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5785546B2 (en) | Method for preventing or treating cerebral ischemia | |
| Dos Santos et al. | Mitochondrial Dysfunction and Alpha‐Lipoic Acid: Beneficial or Harmful in Alzheimer’s Disease? | |
| US9849096B2 (en) | Neuroprotective effect of carotenoids in brain | |
| AU2012235869B2 (en) | Compositions for the treatment of neurologic disorders | |
| EP3560506A1 (en) | Pharmaceutical composition comprising indigo pulverata levis extract or fraction thereof as effective ingredient for preventing or treating inflammatory bowel disease | |
| JP2017529400A (en) | Mangosteen extract or composition for preventing or ameliorating periodontal disease comprising alpha and gamma mangosteen as active ingredients | |
| JP6978325B2 (en) | Composition containing xanthophyll and processed products of Trapa japonica | |
| JP7429739B2 (en) | A composition for preventing and/or improving brain dysfunction containing lutein or its salt and a processed product of a caltrops plant | |
| JP2018503637A (en) | Biphenyl derivatives and uses thereof | |
| JP2006008712A (en) | Neovascularization inhibitor | |
| JP4993515B2 (en) | Oleic acid-containing composition and use thereof | |
| CN112587512A (en) | ASBDV pharmaceutical composition for treating cerebral apoplexy and preparation and application thereof | |
| CN112516119A (en) | ASBD medicine composition for treating cerebral apoplexy and preparation and application thereof | |
| JP2012072132A (en) | Life-extending agent | |
| Pintea et al. | Resveratrol and the human retina | |
| JPWO2018030389A1 (en) | Utilization of NAD-related metabolites | |
| KR102114510B1 (en) | Composition for modulating immunity comprising coenzyme Q10 and omega 3 | |
| JP6093100B2 (en) | Erythrocyte function improver | |
| KR20160081189A (en) | Composition comprising an extract of Eisenia bicyclis for preventing and treating Alzheimers disease | |
| KR20120103306A (en) | Composition for preventing or treating the brain ischemia disease containing extract of terminalia chebula | |
| JP2015110526A (en) | Gingival protective agent | |
| US20240156798A1 (en) | Antioxidant compositions and methods of use | |
| JP2009256282A (en) | Anti-als agent | |
| Harney | Evaluation of trans-resveratrol as a treatment for periodontitis | |
| SIRACUSA et al. | Neuroinflammation and Oxidative Stress in the Traumatic Brain Injury and in the Pathogenesis of Neurodegenerative Diseases: Modulation by Nutritional Supplementation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210402 |